Company: SMNR
Filing Date: 2025-03-20
Form Type: PRE 14A
Source: 0001213900-25-025610
Chunk: 8

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-03-20
Form: PRE 14A
Chunk 8
---
 general meeting”) of Denali Capital Acquisition Corp. (the “Company,” “we,” “us” or “our”) will be held at the offices of US Tiger Securities, Inc. located 437 Madison Avenue, 27 thFloor, New York, NY, at [ ], Eastern time, on [ ], 2025. The extraordinary general meeting will be held for the sole purpose of considering and voting upon the following proposals: • Proposal 1 — The Extension Amendment Proposal— a proposal to amend, by way of special resolution, the amended and restated memorandum and articles of association of the Company in the form set forth in Annex Ato this proxy statement (the “Extension Amendment,” and such proposal, the “Extension Amendment Proposal”) to extend (the “extension”) the date by which the Company must either (i) consummate a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company and one or more businesses or entities (an “initial business combination”) or (ii) cease its operations, except for the purpose of winding up, if it fails to complete such initial business combination and redeem 100% of the Company’s Class A ordinary shares, par value $0.0001 per share (the “Class A ordinary shares”), included as part of the units sold in the Company’s initial public offering that was consummated on April11, 2022 (the “IPO”) from April11, 2025 (the “Termination Date”) to December11, 2025, by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight (8) times by an additional one month each time, unless the closing of the Company’s initial business combination has occurred (such applicable later date, the “Extended Date”), without the need for any further approval of the Company’s shareholders, provided that Denali Capital Global Investments LLC (the “Sponsor”) (or its affiliates or permitted designees or a third party) will deposit into the trust account established in connection with the IPO (the “trust account”) for each such one -monthextension (the “Extension Payment”) $[ ] per public share that remains outstanding and is not redeemed prior to any such one -monthextension, unless the closing of the Company’s initial business combination has occurred, in exchange for a non -interestbearing promissory note payable upon consummation of an initial business combination; and • Proposal 2 — The Adjournment Proposal—